Objective:

To evaluate the efficacy and safety of the investigational gene therapy 4D-150 in patients with wet age-related macular degeneration (AMD).

Approach:

Key Findings:

• Primary endpoint: noninferiority in mean change from baseline in best-corrected visual acuity at 52 weeks.
• Key secondary endpoint: reduction in treatment burden measured by the number of aflibercept injections required.

Interpretation:

The trial aims to demonstrate that 4D-150 can provide comparable visual acuity outcomes with fewer treatment injections than aflibercept.

Limitations:

• Results are pending, with top-line data expected in the first half of 2027.
• The study only includes treatment-naïve patients; results may differ in treatment-experienced populations.

Conclusion:

The completion of enrollment for 4FRONT-1 marks a significant step in evaluating 4D-150 as a potential treatment for wet AMD, with broader implications for patient management and treatment burden.

Sources:

• Retinal Physician
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.